Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | METAP1 | P53582 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468397 | 1.00 | GAA (1.00) | GAAMETAP1PDE3BPDE3ASRC | |
| SCHEMBL11044464 | 0.81 | GAA (0.68) | GAAMETAP1PDE3BPDE3ACYP11B1 | |
| SCHEMBL333847 | 0.78 | GAA (0.63) | GAASRCMAOAALDH1A1ACHE | |
| SCHEMBL5044573 | 0.76 | GAA (0.60) | GAAPDE3BPDE3ATDP2MAOB | |
| SCHEMBL21762103 | 0.74 | GAA (0.58) | GAAMETAP1PDE3BPDE3ASRC | |
| SCHEMBL28634068 | 0.74 | GAA (0.58) | GAASRCTDP2 | |
| SCHEMBL19038489 | 0.73 | GAA (0.58) | GAAMETAP1PDE3BPDE3ACYP11B1 | |
| SCHEMBL10232028 | 0.73 | GAA (0.57) | GAAMETAP1PDE3BPDE3ACYP11B1 | |
| SCHEMBL15906664 | 0.73 | GAA (0.57) | GAAMAOAALDH1A1ACHE | |
| SCHEMBL11045652 | 0.73 | GAA (0.57) | GAATDP2ALDH1A1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| CN-116332910-A | 2-aminopyrimidine derivatives as kinase inhibitors, preparation and use thereof | 江苏威凯尔医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-01 | — | — | US | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-0229510-A1 | Sulfinyl and sulfonyl substituted-3-benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 1987-07-22 | — | — | EP | disclosed |
| US-4659706-A | Sulfinyl and sulfonyl substituted 3-benzazepines | SMITHKLINE BECKMAN CORPORATION (US) | 1987-04-21 | — | — | US | disclosed |
| US-4616011-A | BRADYCARDIAL AND ANTIISCHEMIC AGENTS; CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1986-10-07 | — | — | US | disclosed |
| US-4584293-A | LOWER HEART RATE AND OXYGEN REQUIREMENT | DR. KARL THOMAE GMBH (DE) | 1986-04-22 | — | — | US | disclosed |
| EP-0161604-A2 | Aminotetralin derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
| EP-0065229-B1 | BENZAZEPINES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS | Dr. Karl Thomae GmbH (DE) | 1985-08-07 | — | — | EP | disclosed |
| EP-0146787-A2 | Indole derivatives, medicaments containing these compounds, and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-07-03 | — | — | EP | disclosed |
| US-4490369-A | HYPOTENSIVE, BRRADYCARDIAL | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-12-25 | — | — | US | disclosed |
| EP-0116444-A2 | Improvements in or relating to benzazepine derivatives | ELI LILLY AND COMPANY (US) | 1984-08-22 | — | — | EP | disclosed |
| EP-0065229-A1 | Benzazepines, process for their preparation and their application as pharmaceutical preparations | Dr. Karl Thomae GmbH (DE) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | BACE1, BACE2, BCHE | GAA 6/4885METAP1 438/4885PDE3B 2819/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | GAA 6/4885METAP1 438/4885PDE3B 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.